Strategic Focus Clinical-stage biopharma with a novel antifungal class ( Oromotides ) and a leading candidate olorofim, presenting a compelling growth story for potential partners, CROs, and manufacturing collaborators in translational and late-stage development.

Global Phase 3 Completed enrollment in the global Phase 3 OASIS trial for invasive fungal infections, signaling near-term potential in regulated markets and creating opportunities for supportive commercialization partnerships, medical affairs, and payer discussions.

Orphan and QIDP Status Orphan drug designation in the EU and FDA QIDP and Breakthrough Therapy designations, which can drive priority access, market incentives, and attractive partnering terms for specialty distributors and healthcare systems.

Financial Readiness Significant funding runway with substantial capital raised and mid-range revenue, enabling potential co-development, milestone-rich collaborations, and joint-venture discussions across Europe and the US.

Global Footprint Headquartered in the UK with US and Austria subsidiaries, offering regional collaboration opportunities across multiple jurisdictions, including potential manufacturing, clinical trial execution, and regulatory affairs partnerships.